SCHEMBL30983946

SCHEMBL30983946

CC(C)(C)OC(=O)N1CCN(CCOc2ccc(-c3nc4c(Cl)ncnc4n3Cc3cc(Cl)ccn3)c(Cl)c2)CC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.44
▸ CNR2 P34972 2/20 0.44
▸ GPR4 P46093 1/20 0.41
▸ TBK1 Q9UHD2 2/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ DRD3 P35462 1/20 0.37
▸ SQOR Q9Y6N5 1/20 0.37
▸ GPR119 Q8TDV5 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ DPP4 P27487 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ PIK3CD O00329 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983947 0.90 ADORA2A (0.45) CNR1CNR2GPR4TBK1EPHX2
SCHEMBL30983856 0.90 CNR1 (0.41) CNR1CNR2GPR4EPHX2SQOR
SCHEMBL30983846 0.89 CNR1 (0.47) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30983965 0.83 EPHX2 (0.39) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30983874 0.82 GPR4 (0.38) CNR1CNR2GPR4TBK1EPHX2
SCHEMBL30983781 0.82 CNR1 (0.39) CNR1CNR2GPR4PIK3CD
SCHEMBL30983841 0.81 CNR1 (0.41) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30983836 0.81 CNR1 (0.41) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30984010 0.80 CNR1 (0.43) CNR1CNR2GPR4EPHX2DRD3
SCHEMBL30984061 0.78 HRH4 (0.48) GPR4EPHX2DRD3GPR119KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
Send feedback